Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 246 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Liquid biopsy Clear all

Conditions: Multiple Myeloma
Interventions: Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Ixazomib Citrate, Lenalidomide, Placebo Administration, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 221
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Arroyo Grande, California + 154 more

Conditions: Specimens Are to be Collected From Subjects Who Are Having or Have Had a Fluid or Tissue Removed, a Biopsy or a Blood or Bone Marrow Draw
Interventions: Specimen Collection; Other
Lead sponsor: Sohail Rao; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Edinburg, Texas

Conditions: Hepatocellular Carcinoma Non-resectable
Interventions: Fluorine-18 fluorocholine; Combination Product
Lead sponsor: Queen's Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Intrahepatic Cholangiocarcinoma (Icc)
Interventions: EXOMIC small RNA sequencing, EXOMIC assay (qRT-PCR validation); Diagnostic Test
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions: Not listed
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Friedreich Ataxia
Interventions: Spinal tap for CSF collection, Venipuncture for blood sample; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Cryptogenic Cirrhosis, Cryptogenic Chronic Hepatitis
Interventions: skin punch biopsy collection, Blood collection, Urine sample collection; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Non Small Cell Lung Cancer
Interventions: Liquid biopsy; Diagnostic Test
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Genetic Testing for Cancer Risk, Liquid Biopsy, Magnetic Resonance Imaging of the Whole Body without Contrast, Survey Administration; Procedure · Genetic · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Prostatic Neoplasms
Interventions: 18F- DCFPyL PET/CT; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Patient Reported Outcome Measures, Colorectal Cancer, Pancreatic Cancer, Biliary Tract Cancer, Esophageal Cancer, Metastatic Cancer, Disease Progression, Survival Analysis
Interventions: Observational Cohort; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Blood Draw, Lumbar Puncture; Procedure
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions: Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Capivasertib, Cediranib Maleate, Computed Tomography, Durvalumab, Echocardiography Test, Multigated Acquisition Scan, Olaparib; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 760
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 481 more

Conditions: Inflammation, Vasculitis, Wegener's Granulomatosis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma, Malignant Uterine Neoplasm, Uterine Corpus Carcinosarcoma
Interventions: Biospecimen Collection, Liquid Biopsy, Pap Smear; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Cancer
Interventions: Ability to order FirstLook™, Continuing Medical Education for Lung Cancer; Diagnostic Test · Other
Lead sponsor: Delfi Diagnostics Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Aurora, Colorado • Jacksonville, Florida • Durham, North Carolina

Conditions: Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Lumbar Puncture, Magnetic Resonance Imaging; Procedure · Device
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Esophageal Adenocarcinoma
Interventions: Cryotherapy, Esophagogastroduodenoscopy (EGD), Endoscopic ultrasound (EUS); Procedure
Lead sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Kidney Failure, Chronic, Peritoneal Dialysis Complication, Transplantation, Healthy
Interventions: biopsy sampling; Procedure
Lead sponsor: Heidelberg University; Other
Eligibility: 1 Day to 90 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2028
U.S. locations: 3
States / cities: Birmingham, Alabama • Kansas City, Missouri • Narberth, Pennsylvania

Conditions: Urothelial Carcinoma
Interventions: Not listed
Lead sponsor: Tampere University Hospital; Other
Eligibility: 18 Years to 100 Years
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lung Carcinoma
Interventions: Liquid Biopsy, Low Dose Computed Tomography of the Chest, Survey Administration; Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 50 Years to 80 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Multiple Myeloma
Interventions: liquid biopsy; Genetic
Lead sponsor: Multiple Myeloma Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 1,105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Norwalk, Connecticut • St Louis, Missouri • Hackensack, New Jersey + 1 more

Conditions: Non Small-cell Lung Cancer
Interventions: Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule, Liquid biopsy for aberrant DNA methylation analysis - Known lung cancer for surgical resection, Liquid biopsy for aberrant DNA methylation analysis - Healthy volunteer, Liquid biopsy for aberrant DNA methylation analysis - Benign lung disease; Diagnostic Test
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Diabetes, Obesity
Interventions: Pre-study dietary and exercise instruction., Screening examination and oral glucose tolerance test, Euglycemic clamp, VO2max., Acute exercise bout, Percutaneous needle muscle biopsies; Behavioral · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 30 Years to 59 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Scottsdale, Arizona

Search by objective public record fields.

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

B2RAD Translational Medicine Study

Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma

Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma.

ctDNA Liquid Biopsy for Early Assessment of Residual Disease in HPV-associated Head and Neck Cancer (Clear-HPVca)

Measurement of Frataxin mRNA in Biofluids

Bartonella in Liver Transplant Patients

Liquid Biopsy to Reduce Time to Treatment for Advanced Nonsquamous NSCLC Diagnosed at Outside Sites

Analysis of Whole Body Magnetic Resonance Imaging and Liquid Biopsy for Early Detection of Cancer in Patients With a Strong Family History of Cancer

18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer

Predicting Disease Progression and/or Recurrence in Cancer

Measurement of Relaxin Peptide in Multiple Sclerosis (MS)

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Analysis of Bronchial Tissue and Fluid in Patients With Wegener's Granulomatosis

Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers

Implementing Fragmentomics Into Real World Screening IntervenTions to Evaluate Clinical Utility Among Individuals With Elevated Risk for Lung Cancer

Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell Lung Cancer

Cryotherapy for Malignant Dysphagia in Patients With Advanced Esophageal Cancer

International (Pediatric) Peritoneal Biobank

Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer

Feasibility of Cell-Free DNA Liquid Biopsy in Screening High-Risk Patients for Lung Cancer

MMRF CureCloud Research Initiative

Liquid Biopsy for Early Non-small Lung Cancer Detection

PGC-1 & Muscle Mitochondrial Dysfunction in Diabetes